Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended March 31, 2025
Business Overview: Developer, manufacturer, and seller of technologies and products for life science applications, including research, drug discovery, and bioproduction. Operations are global, with a focus on academic institutions, government laboratories, and pharmaceutical companies.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 | Change |
|---|---|---|---|
| Revenues | $21.8 million | $24.5 million | -11.2% |
| Gross Profit | $12.2 million | $14.8 million | -17.5% |
| Gross Margin | 56.0% | 60.3% | -430 bps |
| Operating Loss | $(49.7) million | $(2.3) million | Significant Increase |
| Net Loss | $(50.3) million | $(4.7) million | Significant Increase |
| Diluted Loss Per Share | $(1.14) | $(0.11) | -936% |
| Cash and Equivalents | $5.5 million | $4.3 million | +28% |
| Total Debt (Current) | $36.0 million | $37.0 million | -2.7% |
| Operating Cash Flow | $3.0 million | $1.4 million | +113% |
Material Changes vs. Prior Period
- Goodwill Impairment: The Company recorded a non-cash goodwill impairment charge of $48.0 million due to a sustained decrease in stock price, recent operating results, and liquidity risks. This is the primary driver of the increased net loss.
- Revenue Decline: Revenues decreased 11.2% year-over-year, attributed to softening worldwide demand from academic research institutions and Contract Research Organizations (CROs).
- Margin Compression: Gross margin declined to 56.0% from 60.3% due to under-absorption of fixed manufacturing costs and a higher mix of lower-margin products.
- Expense Reductions: Operating expenses (excluding impairment) decreased across Sales & Marketing, G&A, and R&D due to cost-cutting measures, including reduced compensation and travel.
- Debt Restructuring: On March 10, 2025, the Company amended its Credit Agreement. The interest rate margin increased (SOFR + 400 bps), and the revolving credit facility is capped at current drawdown levels, preventing additional borrowings.
Outlook, Risks, and Contingencies
- Going Concern Doubt: Management has expressed substantial doubt about the Company's ability to continue as a going concern. The Company must refinance its debt by June 30, 2025, or face an event of default where debt becomes immediately due.
- Refinancing Milestones: The Company is subject to strict milestones to secure refinancing, including obtaining a term sheet by May 23, 2025, and closing by June 30, 2025. As of May 12, 2025, the Company was in compliance with applicable milestones.
- Nasdaq Delisting Risk: The Company received notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement. It has until October 1, 2025, to regain compliance, potentially requiring a reverse stock split.
- Internal Control Weaknesses: Material weaknesses in internal controls over financial reporting (specifically regarding the order-to-cash cycle and inventory counts) remain unremediated as of March 31, 2025.
- Market Risks: Ongoing uncertainty regarding NIH funding levels and increased tariffs on international trade (particularly between the U.S. and China) continue to impact demand and costs.
Investor Verification Checklist
- Refinancing Status: Verify if the Company has secured a term sheet or commitment letter for debt refinancing by the May 23, 2025 deadline.
- Liquidity Position: Monitor cash burn rate and the ability to meet the $3.5 million minimum liquidity requirement under the amended Credit Agreement.
- Stock Price Compliance: Track the common stock bid price to assess the likelihood of meeting Nasdaq's $1.00 minimum requirement by October 1, 2025.
- Revenue Trends: Evaluate whether the softening demand in academic and CRO sectors is stabilizing or worsening in subsequent quarters.
- Internal Controls: Review progress reports on the remediation of material weaknesses in financial reporting controls.